Tumor antigen-specific T-cell expansion is greatly facilitated by in vivo priming.

Tumor antigen-specific T-cell expansion is greatly facilitated by in vivo priming.

Item
http://www.wikidata.org/entity/Q51976944
Generation of tumor-specific T lymphocytes using dendritic cell/tumor fusions and anti-CD3/CD28Use of tumour-responsive T cells as cancer treatment.Adoptive transfer of HER2/neu-specific T cells expanded with alternating gamma chain cytokines mediate tumor regression when combined with the depletion of myeloid-derived suppressor cellsUnraveling graft-versus-host disease and graft-versus-leukemia responses using TCR Vβ spectratype analysis in a murine bone marrow transplantation model.The Antitumor Efficacy of IL2/IL21-Cultured Polyfunctional Neu-Specific T Cells Is TNFα/IL17 Dependent.Insulin-like growth factor-binding protein-2 is a target for the immunomodulation of breast cancer.Concurrent trastuzumab and HER2/neu-specific vaccination in patients with metastatic breast cancerHER-2/neu vaccine-primed autologous T-cell infusions for the treatment of advanced stage HER-2/neu expressing cancers.Surrogate in vitro activation of innate immunity synergizes with interleukin-7 to unleash rapid antigen-driven outgrowth of CD4+ and CD8+ human peripheral blood T-cells naturally recognizing MUC1, HER2/neu and other tumor-associated antigens.Directing dendritic cell immunotherapy towards successful cancer treatment.T cell optimization for the treatment of pancreatic cancer.Generation of T cell effectors using tumor cell-loaded dendritic cells for adoptive T cell therapy.Ex vivo expansion of tumor specific lymphocytes with IL-15 and IL-21 for adoptive immunotherapy in melanoma.Immunization against HIF-1α Inhibits the Growth of Basal Mammary Tumors and Targets Mammary Stem Cells In Vivo.Immunogenicity and safety profiles of genetic vaccines against human Her-2/neu in cynomolgus monkeys.Immunomodulation of breast cancer via tumor antigen specific Th1.Generation of autologous tumor-specific T cells for adoptive transfer based on vaccination, in vitro restimulation and CD3/CD28 dynabead-induced T cell expansion.
P2860

Tumor antigen-specific T-cell expansion is greatly facilitated by in vivo priming.

Item
http://www.wikidata.org/entity/Q51976944
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh-hant
name
Tumor antigen-specific T-cell expansion is greatly facilitated by in vivo priming.
@en
Tumor antigen-specific T-cell expansion is greatly facilitated by in vivo priming.
@nl
type
label
Tumor antigen-specific T-cell expansion is greatly facilitated by in vivo priming.
@en
Tumor antigen-specific T-cell expansion is greatly facilitated by in vivo priming.
@nl
prefLabel
Tumor antigen-specific T-cell expansion is greatly facilitated by in vivo priming.
@en
Tumor antigen-specific T-cell expansion is greatly facilitated by in vivo priming.
@nl
P1433
P1476
P2093
P304
P31
P356
P407
P433
P478
P577
P5875
P698
P356
P1433
P1476
Tumor antigen-specific T-cell expansion is greatly facilitated by in vivo priming.
@en
P2093
P304
P31
P356
10.1158/1078-0432.CCR-06-2083
P407
P433
P478
P577
P5875
P698